09.29.26 -- Capsid Selection And Tissue Targeting Begin Long Before Manufacturing

Cryopreservation is a complex system where biology, materials, and logistics intersect. Learn how early design alignment prevents late-stage failures and ensures scalable therapy success.

Modular vector platforms blend custom transfection with gentle purification. Optimized TFF plus precise chromatography yield high vector recovery across diverse cell and gene therapy applications.

Explore Cas9-mediated homology-directed repair and advancements in gene editing technologies that could significantly broaden the treatment possibilities for various blood disorders.

Watch as speakers share a variety of challenges encountered when closing and automating ancillary processes, and how closed automated platforms improved scalability and reproducibility.

In this segment of Cell & Gene Live, Solving Vector Yield Challenges in In Vivo CGT, Karen Kozarsky, Ph.D., President and CSO of Vector BioPartners, and Robert Bell, Ph.D., CSO of Ascidian Therapeutics, explain how early biological decisions influence downstream manufacturing success.

Bring greater visibility and coordination to scientific development by connecting teams, systems, equipment, samples, and data in real time, while using AI to help build and manage consistent workflows.